GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Fusen Pharmaceutical Co Ltd (HKSE:01652) » Definitions » Capex-to-Operating-Cash-Flow

Fusen Pharmaceutical Co (HKSE:01652) Capex-to-Operating-Cash-Flow : 0.00 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Fusen Pharmaceutical Co Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Fusen Pharmaceutical Co's Capital Expenditure for the six months ended in Dec. 2023 was HK$-50.83 Mil. Its Cash Flow from Operations for the six months ended in Dec. 2023 was HK$-29.52 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Fusen Pharmaceutical Co Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Fusen Pharmaceutical Co's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusen Pharmaceutical Co Capex-to-Operating-Cash-Flow Chart

Fusen Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only 9.82 0.38 2.31 0.22 -

Fusen Pharmaceutical Co Semi-Annual Data
Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.52 - 0.03 - -

Competitive Comparison of Fusen Pharmaceutical Co's Capex-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Fusen Pharmaceutical Co's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fusen Pharmaceutical Co's Capex-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Fusen Pharmaceutical Co's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Fusen Pharmaceutical Co's Capex-to-Operating-Cash-Flow falls into.



Fusen Pharmaceutical Co Capex-to-Operating-Cash-Flow Calculation

Fusen Pharmaceutical Co's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-96.811) / -80.211
=N/A

Fusen Pharmaceutical Co's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-50.832) / -29.517
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fusen Pharmaceutical Co  (HKSE:01652) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Fusen Pharmaceutical Co Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Fusen Pharmaceutical Co's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Fusen Pharmaceutical Co (HKSE:01652) Business Description

Traded in Other Exchanges
N/A
Address
Urban Industrial Zone, Henan Province, Xichuan County, Zhengzhou, CHN
Fusen Pharmaceutical Co Ltd is engaged in manufacturing shuanghuanglian based cold medicine. The product portfolio company includes shuanghuanglian based cold medicine and which includes oral solutions and shuanghuanglian injections, other PCM and western medicine products which include compound ferrous sulphate granules and flunarizine hydrochloride capsules.
Executives
Cao Changcheng 2201 Interest of corporation controlled by you
Quan Xiufeng 2202 Interest of your spouse
Full Bliss Holdings Limited 2101 Beneficial owner
One Victory Investments Limited 2101 Beneficial owner
Cao Zhiming 2201 Interest of corporation controlled by you
Zhou Peilin 2202 Interest of your spouse
Rayford Global Limited 2306 Nominee for another person
Tct (bvi) Limited 2501 Other
The Core Trust Company Limited 2301 Trustee
First Joint Elegant Limited 2101 Beneficial owner
Fung Wai Sze 2202 Interest of your spouse
Lam Yiu Por 2201 Interest of corporation controlled by you

Fusen Pharmaceutical Co (HKSE:01652) Headlines

No Headlines